相关实验视频

Updated: Jul 23, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

开发和评估用于皮肤向和皮肤炎治疗的塔克罗利斯载荷纳米转移体

Jingyu Ren¹, Tao Liu², Bo Bi³

¹Department of Dermatology, The First Hospital of Shanxi Medical University, Taiyuan City, Shanxi Province, 030001, China.

Journal of pharmaceutical sciences

|October 28, 2023

概括

塔克罗利斯装载的纳米转移体凝 (TRL-NTsG) 改善了用于治疗亚托皮炎的局部输送. 这种新的配方增强了药物释放,皮肤透和稳定性,同时减少动物模型中的炎症.

科学领域:

制药科学制药科学
皮肤病学皮肤病学
纳米技术纳米技术

背景情况:

塔克罗利 (TRL) 是一种有效的治疗阿托皮炎 (AD),但面临局部应用的局限性,因为溶解性差和皮肤透率低.
传统的塔克罗利斯配方表现出降低的疗效和潜在的细胞毒性,需要先进的输送系统.

研究的目的:

开发和描述纳米转移体纳米转移体纳入基多凝 (TRL-NTsG) 增强局部递送在亚托皮性皮炎.
评估TRL-NTsG配方的体外,体外和体内性能.

主要方法:

用塔克罗利斯载入的纳米转移体 (TRL-NTs) 的制备和表征,并将其纳入基托凝 (TRL-NTsG).
对TRL-NTs进行形态分析 (TEM),热稳定性 (DSC) 和结构分析 (XRD,FTIR).
评估类型:风湿学,扩散性,可变形性,体外释放性,体外透性,体外细胞毒性,体内皮肤沉积,耳朵厚度和IgE水平.

主要成果:

TRL-NTs形成均分布,负电荷的纳米微粒 (163纳米大小,-27毫伏泽塔电位).
与传统的TRL相比,TRL-NTsG在体外释放 (8倍),体外透 (6倍) 和稳定性都表现出更高的优势.
在体内研究显示,耳朵厚度和IgE水平显著降低,没有观察到毒性,表明配方的有效性和安全性.

结论:

含有塔克罗利斯的纳米转移体凝 (TRL-NTsG) 是一种有前途的先进局部输送系统,用于治疗亚托皮炎.
增强的配方克服了传统塔克罗利斯的局限性,提供了更好的疗效和治疗潜力.

关键词:

亚托邦性皮肤炎 (Atopic Dermatitis) 是一种不良的疾病.盖尔斯 (Gels) 是一种凝.纳米转移体是纳米转移体.塔克罗利慕斯可以使用.专题应用专题应用有毒性有毒性

更多相关视频

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

相关概念视频

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Transdermal Drug Delivery Systems

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...